increased with stage of disease, and the differences between mean levels were found to be significant in stages 1 and 2 versus 3 and 4 (p<0-001). This suggests a positive correlation between the preoperative CEA level and tumour burden defined by pathological staging. When the results were compared with the histological type of lung carcinoma, CEA elevations occurred most frequently with adenocarcinoma, followed by undifferentiated and squamous cell carcinoma, reflecting perhaps the origin of this oncofetal antigen from the endodermally derived bronchial mucosa. These data indicate that preoperative serum CEA levels quantitatively reflect the extent of tumour assessed pathologically at operation and confirm the potential usefulness of this antigen as a biological tumour marker in the management of bronchial neoplasms.
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Carcinoembryonic antigen (CEA) is a highly antigenic glycoprotein which is gaining clinical acceptance as a biological tumour marker for an increasing number of neoplastic disorders. In definition of the extent of disease for adjuvant therapy,7 and as a monitor for recurrent bronchial carcinoma after pulmonary resection.8 9 As a prerequisite to the use of CEA levels in the management of patients with bronchial carcinoma, it is imperative to determine how well serum CEA determinations quantitatively reflect the extent of tumour determined pathologically at operation. The (table 3) . Of the patients with benign, active, inflammatory pulmonary diseases, 20-6% (7/34) had significant elevations compared to normal control subjects. The overall incidence of preoperative CEA elevations (>10 ng/ml) observed in patients with bronchial carcinoma in this study was 73-2% (132/180).
Discussion
There is increasing interest in the study of 
